Cantor Fitzgerald Starts Cubist Pharmaceuticals (CBST) at Sell, Sees Slowing Revenue Trajectory

October 25, 2012 7:52 AM EDT Send to a Friend
Get Alerts CBST Hot Sheet
Price: $73.88 +0.70%

Rating Summary:
    11 Buy, 10 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 16 | New: 41
Trade CBST Now!
Join SI Premium – FREE
Cantor Fitzgerald initiates coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with a Sell. PT $37.00.

The firmcommetns, "CBST ran up following the 2011 Adolor acquisition, but we see the company's revenue trajectory slowing in 2013 as its key revenue driver, Cubicin, matures and competitors begin to take market share. Following the recent revenue miss in 3Q:12, we think there is more downside in the story. It is evident that Cubist is in the midst of an investment phase, which is likely to hurt 2013-2014 earnings expectations."

For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.

Shares of Cubist Pharmaceuticals closed at $45.44 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Hot New Coverage, New Coverage

Related Entities

Cantor Fitzgerald, Earnings

Add Your Comment